Ivy H Song

Summary

Affiliation: GlaxoSmithKline Research and Development
Country: USA

Publications

  1. ncbi request reprint Effect of fosamprenavir-ritonavir on the pharmacokinetics of dolutegravir in healthy subjects
    Ivy Song
    GlaxoSmithKline, Research Triangle Park, North Carolina, USA
    Antimicrob Agents Chemother 58:6696-700. 2014
  2. ncbi request reprint Effects of enzyme inducers efavirenz and tipranavir/ritonavir on the pharmacokinetics of the HIV integrase inhibitor dolutegravir
    Ivy Song
    GlaxoSmithKline, 5 Moore Drive, Research Triangle Park, Durham, NC, 27709, USA
    Eur J Clin Pharmacol 70:1173-9. 2014
  3. pmc Steady-state pharmacokinetics of abacavir in plasma and intracellular carbovir triphosphate following administration of abacavir at 600 milligrams once daily and 300 milligrams twice daily in human immunodeficiency virus-infected subjects
    Graeme Moyle
    St Stephen s Centre, Chelsea and Westminster Hospital, London, United Kingdom
    Antimicrob Agents Chemother 53:1532-8. 2009
  4. pmc Effect of prednisone on the pharmacokinetics of the integrase inhibitor dolutegravir
    Ivy H Song
    GlaxoSmithKline, Research Triangle Park, North Carolina, USA
    Antimicrob Agents Chemother 57:4394-7. 2013
  5. ncbi request reprint Evaluation of the drug interaction potential of aplaviroc, a novel human immunodeficiency virus entry inhibitor, using a modified cooperstown 5 + 1 cocktail
    Brendan M Johnson
    GlaxoSmithKline, Research Triangle Park, NC 27709, USA
    J Clin Pharmacol 46:577-87. 2006

Collaborators

Detail Information

Publications5

  1. ncbi request reprint Effect of fosamprenavir-ritonavir on the pharmacokinetics of dolutegravir in healthy subjects
    Ivy Song
    GlaxoSmithKline, Research Triangle Park, North Carolina, USA
    Antimicrob Agents Chemother 58:6696-700. 2014
    ..In the INI-resistant population, as a cautionary measure, alternative combinations that do not include FPV-RTV should be considered. (This study has been registered at ClinicalTrials.gov under identifier NCT01209065.). ..
  2. ncbi request reprint Effects of enzyme inducers efavirenz and tipranavir/ritonavir on the pharmacokinetics of the HIV integrase inhibitor dolutegravir
    Ivy Song
    GlaxoSmithKline, 5 Moore Drive, Research Triangle Park, Durham, NC, 27709, USA
    Eur J Clin Pharmacol 70:1173-9. 2014
    ..Dolutegravir (DTG) is an unboosted, integrase inhibitor for the treatment of HIV infection. Two studies evaluated the effects of efavirenz (EFV) and tipranavir/ritonavir (TPV/r) on DTG pharmacokinetics (PK) in healthy subjects...
  3. pmc Steady-state pharmacokinetics of abacavir in plasma and intracellular carbovir triphosphate following administration of abacavir at 600 milligrams once daily and 300 milligrams twice daily in human immunodeficiency virus-infected subjects
    Graeme Moyle
    St Stephen s Centre, Chelsea and Westminster Hospital, London, United Kingdom
    Antimicrob Agents Chemother 53:1532-8. 2009
    ..Women had higher intracellular CBV-TP exposure than did men...
  4. pmc Effect of prednisone on the pharmacokinetics of the integrase inhibitor dolutegravir
    Ivy H Song
    GlaxoSmithKline, Research Triangle Park, North Carolina, USA
    Antimicrob Agents Chemother 57:4394-7. 2013
    ..No dose adjustment is required for DTG coadministered with prednisone. (This study has been registered at ClinicalTrials.gov under registration no. NCT01425099.). ..
  5. ncbi request reprint Evaluation of the drug interaction potential of aplaviroc, a novel human immunodeficiency virus entry inhibitor, using a modified cooperstown 5 + 1 cocktail
    Brendan M Johnson
    GlaxoSmithKline, Research Triangle Park, NC 27709, USA
    J Clin Pharmacol 46:577-87. 2006
    ..63). No significant inhibition of CYP1A2, CYP2C9, CYP2C19, or CYP2D6 enzyme activity was observed. Mild inhibition of CYP3A isozymes should not preclude the use of concomitant CYP3A substrates in future clinical studies with aplaviroc...